Unknown

Dataset Information

0

Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.


ABSTRACT: We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.Placental growth factor was evaluated at baseline and study week 4 (after 3 weeks treatment) in an exploratory analysis of data from a randomized phase 2 study of motesanib 125 mg once daily plus carboplatin/paclitaxel and in a prespecified analysis of data from a randomized, double-blind phase 3 study of motesanib 125 mg once daily plus carboplatin/paclitaxel vs placebo plus carboplatin/paclitaxel (MONET1). Associations between fold-change from baseline in placental growth factor and overall survival were evaluated using Cox proportional hazards models.In the phase 2 study, serum placental growth factor increased from baseline a mean 2.8-fold at study week 4. Patients with ?2.2-fold change from baseline in placental growth factor (n?=?18) had significantly longer overall survival than those with <2.2-fold change (n?=?19; 22.9 vs 7.9 months; hazard ratio, 0.30; 95% CI, 0.12-0.74; P?=?0.009). Consequently, placental growth factor was investigated as a pharmacodynamic biomarker in the phase 3 MONET1 study. There was no association between log-transformed placental growth factor fold-change from baseline to week 4 (continuous variable) and overall survival (hazard ratio, 0.98; 95% CI, 0.79-1.22; P?=?0.868). MONET1 did not meet its primary endpoint of overall survival. Likewise, median overall survival was similar among patients with ?2.0-fold change in placental growth factor (n?=?229) compared with <2.0-fold change (n?=?127; 14.8 vs 13.8 months; hazard ratio, 0.88; 95% CI, 0.67-1.15, P?=?0.340).Our results illustrate the challenges of successfully translating phase 2 biomarker results into phase 3 studies.ClinicalTrials.gov NCT00460317, NCT00369070.

SUBMITTER: Bass MB 

PROVIDER: S-EPMC4196848 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.

Bass Michael B MB   Yao Bin B   Hei Yong-Jiang YJ   Ye Yining Y   Davis Gerard J GJ   Davis Michael T MT   Kaesdorf Barbara A BA   Chan Sabrina S SS   Patterson Scott D SD  

PloS one 20141014 10


<h4>Purpose</h4>We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.<h4>Experimental design</h4>Placental growth factor was evaluated at baseline and study week 4 (after 3 weeks treatment) in an exploratory analysis of data from a randomized phase 2 study of motesanib 125 mg once daily plus carboplatin/paclitaxel and in a prespecified analysis of data f  ...[more]

Similar Datasets

| S-EPMC6071180 | biostudies-literature
| S-EPMC6471174 | biostudies-literature
| S-EPMC7539317 | biostudies-literature
| S-EPMC5244743 | biostudies-literature
| S-EPMC5666703 | biostudies-literature
| S-EPMC3359057 | biostudies-literature
| S-EPMC5268362 | biostudies-literature
| S-EPMC3969886 | biostudies-literature
| S-EPMC3477383 | biostudies-other
| S-EPMC5771500 | biostudies-literature